Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

NCT ID: NCT04141306

Last Updated: 2019-10-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-11-30
• Study Completion Date: 2019-12-31

Brief Summary

Bone radioiodine (RAI) uptake without structural abnormality in thyroid cancer (TC) patients may be related to false positive or to microscopic foci of metastatic tissue. In such cases, outcome is reported to be excellent.

Indeed, Robenshtok et al. reported a serie of patients with RAI-avid bone metastases of TC without structural abnormality on imaging studies who have more favorable long-term prognosis than those harbouring structurally visible bone metastases and do not undergo skeletal-related complications.

The investigators report the case of Mrs D., who had been operated for a pathologic tumor stage 3: pT3(m) poorly differentiated TC at the age of 43. The first post-therapeutic whole body scan revealed 3 foci of bone uptake (right clavicle, L2, L3). The elevated level of thyroglobulin (157ng/mL) favoured the hypothesis of bone metastases despite the absence of any structural lesion on CT and MRI. She received 7 courses of radioiodine therapy. The right clavicle RAI uptake persisted, and subsequent CT disclosed an osteolytic lesion which was treated by radiofrequency and external beam radiation. Twenty-five years after the diagnosis, she has a persistent morphological disease with a 30x8mm progressive lesion on the right clavicle, for which surgery is planned.

The aim of the present study is to describe the natural history and evolution of radioiodine avid bone metastases from thyroid cancer without structural abnormalities and to identify prognosis factors.

Conditions

Bone Metastases; Thyroid Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Interventions

Administrative data

Evaluation of month and year of birth, sex, referent doctor and surgeon

Intervention Type: OTHER

Clinical data

Evaluation of diagnostic circumstances, vital status at last follow up

Intervention Type: OTHER

Histological data

Evaluation of Pathology report of thyroid surgery

Intervention Type: OTHER

Imaging data

Evaluation of scintigraphy, MRI, scan

Intervention Type: OTHER

Biological data

Evaluation of thyroglobulin, antithyroglobulin antibodies

Intervention Type: OTHER

Further treatment

Evaluation of surgery, radiotherapy, targeted therapy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Differentiated thyroid cancer
• Ablation therapy with post dose scintigraphy
• At least one radioiodine bone uptake without structural correlation on high-resolution imaging

Exclusion Criteria

• A single radio iodine bone uptake with structural correlation on imaging
• Diagnosis of bone metastasis after a skeletal related event including spinal cord compression, pathological fracture, need for external beam radiation, surgery to bone, or development of hypercalcemia of malignancy
• Follow up less than 6 months
• Missing data in medical record

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Claire BOURNAUD, MD

Role: CONTACT

claire.bournaud-salinas@chu-lyon.fr

4 72 35 69 99 ext. +33

Claire MARX

Role: CONTACT

claire.marx@chu-lyon.fr

Other Identifiers

69HCL19_1919

Identifier Type: -

Identifier Source: org_study_id